Damora Therapeutics Quarterly Cash Flow Statement
NASDAQ: DMRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
21.08+0.52 (+2.53%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Damora Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Damora Therapeutics generated -$21.9 million of operating cash flow. That left free cash flow of -$21.9 million.
Summary generated from market data by MetaCap's automated system. Methodology
Damora Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -31.20M | -27.78M | -200.74M | -3.10M | -3.40M | -2.53M | -6.74M | -3.90M | -5.30M | -5.48M | -6.47M | -8.10M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 6.00K | 5.00K | 6.00K | 6.00K | 6.00K | 5.00K | 5.00K | 6.00K | 5.00K | 5.00K | 23.00K | 211.00K |
| Stock-Based Compensation | 6.14M | 3.13M | 483.00K | 164.00K | 172.00K | 179.00K | 308.00K | 681.00K | 891.00K | 1.36M | 1.09M | 1.46M |
| Change in Working Capital | 2.10M | 665.00K | -712.00K | 401.00K | 570.00K | -346.00K | -1.29M | 583.00K | 124.00K | 215.00K | -3.52M | -718.00K |
| Operating Cash Flow | -21.87M | -20.60M | 566.00K | -2.62M | -2.24M | -2.44M | -4.94M | -3.65M | -4.10M | -5.94M | -11.47M | -8.45M |
| Investing Cash Flow | — | — | — | — | — | — | 0 | 0 | 6.00M | 5.65M | 9.58M | 8.29M |
| Financing Cash Flow | 29.50M | 295.92M | — | — | — | — | — | — | — | — | 0 | 171.00K |
| Net Change in Cash | 7.64M | 275.32M | 250.04M | -2.62M | -2.24M | -2.44M | -4.94M | -3.65M | 1.90M | -286.00K | -1.89M | 2.00K |
| Free Cash Flow | -21.87M | -20.60M | 566.00K | -2.62M | -2.24M | -2.44M | -4.94M | -3.65M | -4.10M | -5.94M | -11.47M | -8.45M |
This table shows 12 quarterly periods of Damora Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow DMRA's reporting calendar. What is a cash flow statement?